NorthWest Biotherapeutics Inc (NWBO)

[Basin Street Blues]

From FT
'Last week investors saw the first glimpse of Davis’s strategy when Merck agreed to pay $11.5bn for Acceleron Pharma, a biotech company that develops protein-based therapies to treat a rare blood pressure disorder and some cancers. Davis said the deal would help to diversify Merck’s portfolio and that he was scouring for other targets to help the company contend with the looming patent cliff.

“I’m confident we have the firepower, the capability, the focus and urgency to do that,” Davis told the Financial Times. “This is the first step on a journey to continue to build out our pipeline so that we have the ability to grow sustainably well into the next decade?.?.?.?We won’t be limited by the balance sheet.”